Menu Search
Equities

BioInvent International AB

BINV:STO

BioInvent International AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)44.00
  • Today's Change-1.20 / -2.65%
  • Shares traded118.98k
  • 1 Year change+148.87%
  • Beta0.7271
Data delayed at least 15 minutes, as of Sep 23 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The 2 analysts offering 12 month price targets for BioInvent International AB have a median target of 72.50, with a high estimate of 90.00 and a low estimate of 55.00. The median estimate represents a 64.77% increase from the last price of 44.00.
High104.5%90.00
Med64.8%72.50
Low25.0%55.00

Earnings history & estimates in SEK

On Feb 22, 2024, losses of -1.48 per share.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate-7.46%
BioInvent International AB reported annual 2022 losses of -0.69 per share on Feb 22, 2023.
Average growth rate+18.02%
More ▼

Revenue history & estimates in SEK

of 20.64m. This bettered the 7.00m estimate of the one analyst covering the company.
Average growth rate+421.94%
BioInvent International AB (publ) had revenues for the full year 2023 of 71.46m. This was 78.09% below the prior year's results.
Average growth rate+368.68%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.